Advertisement

Reduction of Adverse Events With Phosphodiesterase 5 Inhibitors Post LVAD Implantation: Is It Time for a Randomized Trial?

      Abstract

      The improved survival of patients with advanced heart failure after left ventricular assist device (LVAD) implantation together with the scarcity of donor hearts has significantly increased the population of LVAD-supported patients. However, despite the improvement in LVAD technology and the advent of third-generation continuous flow LVADs, complications such as those related to hemocompatibility and stroke rates remain ongoing clinical challenges. Thus, improvement in LVAD technology should be coupled with innovative medical management to further reduce adverse events. We have previously shown a strong association between post LVAD implant phosphodiesterase-5 inhibitors (PDE-5i) use and fewer thrombotic events, as well as improved survival in 2 observational studies. We caution, nevertheless, the use of PDE-5i based on these observations and encourage clinicians to support enrollment in a randomized control trial. A randomized control trial will determine the efficacy and safety of PDE-5i use after implantation in patients with a centrifugal flow LVAD.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hariri IM
        • Dardas T
        • Kanwar M
        • Cogswell R
        • Gosev I
        • Molina E
        • et al.
        Long-term survival on LVAD support: device complications and end-organ dysfunction limit long-term success.
        J Heart Lung Transplant. 2022; 41: 161-170
        • Cho SM
        • Mehaffey JH
        • Meyers SL
        • Cantor RS
        • Starling RC
        • Kirklin JK
        • et al.
        Cerebrovascular events in patients with centrifugal-flow left ventricular assist devices: propensity score-matched analysis from the INTERMACS Registry.
        Circulation. 2021; 144: 763-772
        • Netuka I
        • Mehra MR
        Ischemic stroke and subsequent thrombosis within a HeartMate 3 left ventricular assist system: a cautionary tale.
        J Heart Lung Transplant. 2018; 37: 170-172
        • Mehra MR
        • Uriel N
        • Naka Y
        • Cleveland Jr., JC
        • Yuzefpolskaya M
        • Salerno CT
        • et al.
        A fully magnetically levitated left ventricular assist device final report.
        N Engl J Med. 2019; 380: 1618-1627
        • Xanthopoulos A
        • Tryposkiadis K
        • Triposkiadis F
        • Fukamachi K
        • Soltesz EG
        • Young JB
        • et al.
        Postimplant phosphodiesterase type 5 inhibitors use is associated with lower rates of thrombotic events after left ventricular assist device implantation.
        J Am Heart Assoc. 2020; 9e015897
        • Xanthopoulos A
        • Wolski K
        • Wang Q
        • Blackstone EH
        • Randhawa VK
        • Soltesz EG
        • et al.
        Postimplant phosphodiesterase-5 inhibitor use in centrifugal flow left ventricular assist devices.
        JACC Heart Fail. 2022; 10: 89-100
        • Gulati G
        • Kiernan MS
        Phosphodiesterase-5 inhibitor therapy for left ventricular assist device patients: more data, more questions.
        J Am Heart Assoc. 2020; 9e017585
        • Triposkiadis F
        • Xanthopoulos A
        • Skoularigis J
        • Starling RC
        Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
        Heart Fail Rev. 2022 Apr 18; (Online ahead of print)https://doi.org/10.1007/s10741-022-10239-5
        • Fanaroff AC
        • Califf RM
        • Harrington RA
        • Granger CB
        • McMurray JJV
        • Patel MR
        • et al.
        Randomized trials versus common sense and clinical observation: JACC review topic of the week.
        J Am Coll Cardiol. 2020; 76: 580-589
        • Jorde UP
        • Saeed O
        Association of Improved outcomes and phosphodiesterase-5 inhibition during contemporary LVAD support: end of the beginning?.
        JACC Heart Fail. 2022; 10: 101-103